Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Document › Details

GlycoEra AG. (1/5/21). "Press Release: GlycoEra AG Announces Its Incorporation and Welcomes Ganesh Kaundinya as Inaugural Member of the Board of Directors". Schlieren.

Organisations Organisation GlycoEra AG
  Group GlycoEra (Group)
  Organisation 2 LimmaTech Biologics AG
Products Product CustomGlycan glycoengineering platform
  Product 2 biopharmaceutical
Person Person Gambillara Fonck, Veronica (Bellevue 202210–Partner at Pureos Partners before GlycoEra + LimmaTech + GlycoVaxyn)
     


GlycoEra AG announced today its incorporation with the purpose of leveraging a proprietary glycoengineering platform to develop a pipeline of novel biologics for inflammatory disease, autoimmune disorder and immuno-oncology indications. The company has been founded as a product development-focused spin-out of LimmaTech Biologics AG and has obtained a world-wide exclusive license from LimmaTech to its CustomGlycan Platform and associated assets.

“We have established GlycoEra to unlock the full value of the CustomGlycan Platform by driving a range of product candidates toward clinical proof-of-concept,” stated Veronica Gambillara Fonck, PhD, CEO and co-founder of GlycoEra. “Based on our years of expertise in understanding the role glycans play in therapeutic development, we believe that our specialized glycoengineering team, with its proven track-record, will demonstrate the platform’s value and potential in producing new therapies.”

Amir Faridmoayer, GlycoEra’s Chief Scientific Officer and co-founder, added: “As the understanding of glycobiology and glycoimmunology increases, it is evident that glycans are essential for regulating different biological pathways in humans. The translation of this knowledge into effective therapeutics has been hampered due to the complexity of producing specific glycan structures with high homogeneity. GlycoEra’s CustomGlycan Platform enables us to precisely and selectively target specific glycan-mediated biological pathways to develop novel products for challenging diseases.”

GlycoEra is pleased to announce that biopharmaceutical veteran, Ganesh Kaundinya, PhD, a founder and most recently the Chief Operating Officer and Chief Scientific Officer of Momenta Pharmaceuticals (lately acquired by Johnson and Johnson), has joined as the first member of the company’s Board of Directors. He has extensive experience in biopharmaceutical company formation, growth, product development and commercialization.

Dr. Kaundinya commented: “I am looking forward to working closely with the newly-established GlycoEra team to unlock the power of the technology and support the company as they develop novel biological products targeting glycan-mediated biology for a range of indications.”


About GlycoEra AG

For further information, visit www.glycoera.com


Company contact:

GlycoEra AG
Veronica.gambillara@glycoera.com
Phone: +41 44 733 85 75

   
Record changed: 2023-06-05

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for GlycoEra (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px




» top